Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine
Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine
复制标题
DOI：
10.1016/j.vaccine.2012.08.003
复制
发表时间：
2012-09-28
期刊：
影响因子：
5.5
通讯作者：
Mirazimi, Ali
中科院分区：
文献类型：
--
作者：
Mousavi-Jazi, Mehrdad;Karlberg, Helen;Mirazimi, Ali
克里米亚-刚果出血热病毒（CCHFV）因其高致死率、高传播率和广泛的地理分布，对公共卫生构成极大威胁。目前尚无针对CCHF的特异性抗病毒治疗。这项研究首次深入分析了注射保加利亚灭活疫苗后健康个体的细胞和体液免疫应答，保加利亚灭活疫苗是目前唯一可用的CCHFV疫苗。通过IFN-γ ELISpot测定，接种疫苗的个体产生了稳健的抗CCHFV特异性T细胞活性。IFN-γ分泌T细胞的频率在接种四剂疫苗后比单剂疫苗后高10倍。在第一次给药后观察到高水平的CCHFV抗体，但需要重复给药以获得对CCHFV具有中和活性的抗体。然而，这些组中的中和活性较低。(C)2012爱思唯尔有限公司保留所有权利。
Crimean-Congo hemorrhagic fever virus (CCHFV) poses a great threat to public health due to its high mortality and transmission rate and wide geographical distribution. There is currently no specific antiviral therapy for CCHF. This study provides the first in-depth analysis of the cellular and humoral immune response in healthy individuals following injection of inactivated Bulgarian vaccine, the only CCHFV vaccine available at present. Vaccinated individuals developed robust, anti-CCHFV-specific T-cell activity as measured by IFN-gamma ELISpot assay. The frequency of IFN-gamma secreting T-cells was 10-fold higher in individuals after vaccination with four doses than after one single dose. High levels of CCHFV antibodies were observed following the first dose, but repeated doses were required to achieve antibodies with neutralizing activity against CCHFV. However, the neutralizing activity in these groups was low. (C) 2012 Elsevier Ltd. All rights reserved.